Leading brokers name 3 ASX shares to buy today

The ResMed Inc (ASX:RMD) share price is one of three that leading brokers have tipped to climb higher…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many of Australia's leading brokers are back in the office again after the Christmas break and have been busy adjusting their recommendations to account for new data and developments.

Three shares that have fared well and been given buy ratings are listed below. Here's why they are in favour with brokers:

Pilbara Minerals Ltd (ASX: PLS)

A note out of the Macquarie equities desk reveals that its analysts have retained their outperform rating and $1.20 price target on this lithium miner's shares after its update last week. The broker appears to be pleased that strong demand has led to the company investigating the need for further processing expansions. And although its equity raising is expected to dilute earnings per share, the broker remains positive on Pilbara Minerals due to positive long term demand. While I do like Pilbara Minerals, I intend to see how lithium prices fare in 2019 before considering an investment.

ResApp Health Ltd (ASX: RAP)

According to a note out of Morgans, its analysts have a (high risk) add rating and 24 cents price target on this digital health company's shares. The broker made the move after ResApp announced that it has submitted its CE Mark technical file that is required to allow commercial sales to commence. In addition to this, the broker notes that there are two potential catalysts on the horizon that could move its shares. These are the outcomes of its adult respiratory study in Australia and the clinical adjudication for croup.

ResMed Inc (ASX: RMD)

Analysts at Morgan Stanley have retained their overweight rating and increased the price target on its U.S. shares to US$126 (approximately $17.70 for its ASX listed CDIs). According to the note, the broker has reviewed the healthcare sector ahead of earnings season and sees no reason why ResMed's strong earnings growth trajectory will be disrupted. In light of this, the broker believes that its rich valuation will remain in place for some time to come. I agree with Morgan Stanley on ResMed and think it is one of the best buy and hold options on the local market right now.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Two men laughing while bouncing on bouncy balls
Share Market News

Can these 2 ASX 200 shares rebound after reaching record lows?

Brokers see 30-50% upside for the battered stocks.

Read more »

ASX share investor sitting with a laptop on a desk, pondering something.
Broker Notes

These 2 ASX All Ords shares tripled in value last year. Can they keep going?

Both of these ASX shares more than tripled their market capitalisations in 2025.

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Share Market News

5 things to watch on the ASX 200 on Wednesday

It looks set to be another tough session for Aussie investors on hump day.

Read more »

a man wearing a suit holding up his glasses
Opinions

5 ASX shares I'd buy with $5,000 this week

These stocks are in the spotlight this week.

Read more »

A young well-dressed couple at a luxury resort celebrate successful life choices.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors kept up the selling this session.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Morgans says these ASX 200 shares can rise 20%+

The broker says these shares could offer major upside.

Read more »

Three women athletes lie flat on a running track as though they have had a long hard race where they have fought hard but lost the event.
Broker Notes

Brokers rate 2 ASX All Ords rippers of 2025: Is their phenomenal run over?

Both of these ASX shares more than tripled in value last year.

Read more »

a woman puts her hand to her chin and looks to the side deep in thought as though pondering something significant.
Broker Notes

2 ASX 200 gold shares to buy and 1 to sell: experts

After exceptional share price growth for 2 years, experts say investors need to choose their gold stocks carefully.

Read more »